Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.

Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

Canada's recreation cannabis sales grew by 19% in March to reach CA$181.1 million ($131.5 million), ahead of most U.S. states, according to Cantor Fitzgerald.Analyst Pablo Zuanic said that Canada's March sales data was significantly ahead of Cantor's mid-single digit estimate, partly due to pantry loading, but also on account of continued Cannabis 2.0 rollouts.Ratings And Price Targets Cantor analyst Pablo Zuanic maintained the following ratings and price targets on cannabis stocks:Overweight * Aurora Cannabis Inc. (NYSE: ACB) with a CA$27 price target. * Aphria Inc. (NYSE: APHA) with a CA$9.55 price target. * OrganiGram Holdings Inc (NASDAQ: OGI) with a price target of CA$5.60. Neutral * Canopy Growth Corp (NYSE: CGC) with a price target of CA$25. * Tilray Inc (NASDAQ: TLRY) with a price target of $8. Underweight * Hexo Corp (NYSE: HEXO) with a price target of CA$0.72.Cantor's Cannabis Takeaways Comparing Canada's 17th month of recreational cannabis sales with Colorado's figures indicates that the country's market may grow to CA$14 billion by the end of 2024, Zuanic said in the industry note.So far, the best performers in the first quarter are Aphria, with 53% sales growth, and Aurora Cannabis and Tilray, with sales growth in the mid-20% range, the analyst said.Canopy Growth is scheduled to report its March quarter results Friday.Zuanic named Aphria and Aurora Cannabis as top picks.Related Links: Canopy Growth Set To Become Cannabis Sector Leader, Says BofAThe Week In Cannabis: A Great Week For Stocks Driven By Confusion, Aurora's Rally, New Advisors To BenzingaCourtesy photo * Analista: Aphria y Aurora Cannabis Posicionados para Liderar Ventas en CanadaLatest Ratings for APHA DateFirmActionFromTo May 2020Cantor FitzgeraldMaintainsOverweight May 2020Cantor FitzgeraldMaintainsOverweight Apr 2020CIBCMaintainsNeutral View More Analyst Ratings for APHA View the Latest Analyst Ratings See more from Benzinga * Cantor Fitzgerald Says Aurora Cannabis Sell-Off Creates Entry Point * Monthly Canadian Cannabis Sales Increased Ahead Of Coronavirus Pandemic(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.

Canadian cannabis company Aphria Inc (NYSE: APHA) announced Tuesday it will transfer its stock from the New York Stock Exchange to the Nasdaq exchange after the market closes June 5.What To Know"This move is a reflection of our ongoing commitment to find cost effective ways of operating so we can continue to deliver long-term value to shareholders," CEO Irwin D. Simon said in a press release. "Additionally, as a purpose driven Company, we believe Nasdaq will be a good fit for Aphria, particularly given our focus on, and the progress we have made, integrating ESG practices across our business."More than 76% of Nasdaq-listed companies report on ESG metrics.Why It's ImportantIn the last few years, some big names have defected from Intercontinental Exchange Inc's (NYSE: ICE) NYSE to the Nasdaq, including PepsiCo, Inc. (NASDAQ: PEP) in 2017 and Sanofi SA (NASDAQ: SNY) in 2019. Investopedia cites financial and logistical advantages to listing on the Nasdaq, which has smaller fees and less stringent criteria.Still, the NYSE claims the gains go both ways. According to its website, about $1.3 trillion in equity market cap has transferred from the Nasdaq to the NYSE since 2000.What's NextAphria will continue to trade under ticker symbol APHA and maintain its listing on the Toronto Stock Exchange.The stock trades around $4.28 per share.Don't miss this opportunity to connect with THE cannabis movers and shakers from across the globe during Benzinga's first Virtual Cannabis Capital Conference on June 1.Español: Empresa de Cannabis Aphria (APHA) Mudara Sus Acciones del NYSE al NasdaqSee more from Benzinga * NYSE To Delist Bankrupt Hertz: Report * Matthew Stafford Is Selling A 7,700-Square-Foot House With Michigan's Biggest Infinity Pool * Fauci Calls Moderna's Coronavirus Vaccine Candidate 'Quite Promising'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.

(Bloomberg) -- Green Growth Brands Inc., a cannabis company that made a failed pursuit for Aphria Inc., filed for bankruptcy protection after warning investors it was in “serious financial difficulty.”The company said in a statement Wednesday its “severe liquidity crisis in the face of material matured and maturing debt” was made worse by the Covid-19 pandemic.“The continuing operations of the company are dependent upon its ability to continue to raise adequate financing, to commence profitable operations, and to repay its liabilities arising from normal business operations as they become due,” Green Growth said. It requested court protection through the Companies’ Creditors Arrangement Act in Canada. Ernst & Young Inc. was appointed as the monitor in the proceedings.All Js Greenspace LLC, one of GGB’s existing secured lenders, agreed to a debtor-in-possession loan facility of as much as $7.2 million, Green Growth said. Its shares tumbled as much as 64% to 2 Canadian cents in Toronto.Green Growth made a splashy attempt to take over one of the biggest players in the Canadian cannabis industry with a C$2.4 billion hostile bid for Aphria in January 2019. That came after a short-seller attack triggered a plunge that erased more than half of Aphria’s market value. Since then, Aphria has posted three consecutive quarters of profitability on an Ebitda basis.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA), a leading global cannabis company, today announced that it will transfer its stock exchange listing from the New York Stock Exchange ("NYSE") to The Nasdaq Global Select Market ("Nasdaq"), effective Friday, June 5, 2020, after the market close. The Company expects its common stock will begin trading as a Nasdaq-listed security at market open on Monday, June 8, 2020 and will continue to be listed under the ticker symbol "APHA." This transition will not impact the Company's primary listing on the Toronto Stock Exchange (TSX: APHA).

CALGARY , May 25, 2020 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of cannabis lifestyle accessories, is pleased to announce that the Canna Cabana retail cannabis store located in Unit #2 at 2400 Guelph Line in Burlington, Ontario (the "Burlington Store") will be opening on Wednesday, May 27, 2020 . It marks the sixth branded Canna Cabana location in Ontario and the Company's 35th retail cannabis store across Canada .

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.

Aphria (NYSE: APHA) will no longer be traded through that most classic of American financial institutions, the New York Stock Exchange (NYSE). On Tuesday, the company announced that its shares will move to the Nasdaq (NASDAQ: NDAQ), beginning at market open on Monday, June 8. The stock will retain its current ticker symbol of APHA.

Canada-based cannabis company Aphria Inc. said Tuesday its U.S.-listed stock will leave the New York Stock Exchange in favor of the Nasdaq Global Select Market, effective after the June 5 close. The stock will begin trading on the Nasdaq under the same ticker symbol "APHA" on June 8. "This move is a reflection of our ongoing commitment to find cost effective ways of operating so we can continue to deliver long-term value to shareholders," said Chief Executive Irwin Simon. Aphria's stock rose 4.0% in premarket trading. It has gained 5.8% over the past three months through Friday, while the Cannabis ETF has advanced 3.6% and the S&P 500 has lost 5.2%.

Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

As most of North America goes back to work following shutdowns due to the coronavirus outbreak, one sector that survived the economic weakness was the cannabis sector. The sector was generally seen as essential by various governments due to the medical cannabis aspect while other retailers were forced to close.The Canadian cannabis sector continues to see sales grow as more retail stores are opened and Cannabis 2.0 products are rolled out. For January/February, sales were roughly C$150 million per month. The country is now on the pace to top C$2 billion in annual sales this year.In April, the sector now has 1.5x the number of retail stores as recently as November with more stores on the way in the key province of Ontario. In addition, the Cannabis 2.0 rollout continues to provide another boost to sales.The bigger question for the sector was liquidity as financial markets became less willing to lend to firms in a developing market such as cannabis with the onset of a recession. Yet, despite weak access to affordable capital, the strong sector sales set up the players with excess cash to survive and thrive in this period. We’ve delved into these Canadian cannabis stocks with two stocks to consider here and one to avoid. Using TipRanks’ Stock Comparison tool, we lined up the three alongside each other to get the lowdown on what the near-term holds for these cannabis players.Aphria (APHA)We will start with Aphria, a Canadian cannabis producer with a strong cash balance sheet and a solid operating business. The stock has started a solid rally off the $3 lows due to encouraging signs in the cannabis sector.The company ended the last quarter with C$600 million in cash on the balance sheet. On the negative side, Aphria did have C$465 million in debt, but the key at this point in the cycle is the liquidity while smaller competitors lack access to reasonable funding.The company made the recent deal in May to convert C$127.5 million worth of convertible debt by issuing 18.7 million shares for a conversion price of $4.84 per share. The deal saves C$6.7 million in annual interest costs.Analysts are forecasting FY20 revenues reaching $390 million followed by nearly $500 million in FY21. The stock has a market cap below $1 billion so lots of value exists here.The stock is one of the cheapest in the Canadian cannabis space and Aphria is one of only a few cannabis companies with a net cash position above C$150 million. The stock rally to $4 appears the start of extended gains as Aurora Cannabis changed the sentiment in the Canadian cannabis sector.Overall, APHA holds a Moderate Buy rating from the analyst consensus, based on 5 “buy” ratings and 2 “holds.” Shares are selling for $4.19, and the average price target of $5.45 implies about 30% upside potential. (See APHA stock analysis on TipRanks)Canopy Growth (CGC)As with a lot of sectors, the rich only got richer during the downturn. In this case, Canopy Growth saw Constellation Brands cash in warrants providing more cash for financing growth. The large Canadian cannabis company ended the December quarter with a cash hoard of C$2.26 billion and the C$245 million from the warrants will further boost the balance sheet. The biggest question for Canopy Growth is whether the new management team can drastically cut the cash burn from large EBITDA losses.The news wasn’t really surprising with the strike price at only C$12.9783 per share for 18,876,901 warrants to purchase Canopy Growth when the stock was trading above C$21.The warrants equated to 5.1% of the outstanding shares of Canopy Growth placing the Constellation Brands position up to 38.6%. The company owns warrants to purchase another 139,745,453 shares for a controlling position of 55.8%.With the extra cash, Canopy Growth remains a solid stock to own here at $18. My recommendation has recently held to pick up the stock on weakness as the company looks to grow revenues while substantially cutting the EBITDA losses from the C$92 million in the last quarter. As the company gets closer to breakeven, the stock will regain a lot of the previous interest in the cannabis space that originally drove the stock above $50. (See Canopy stock analysis on TipRanks)Tilray (TLRY)The big-name Canadian cannabis company in the opposite position is Tilray The company has limited cash and a highly unprofitable business.Tilray generated $52 million in Q1 revenues and analysts forecast Q2 revenues of ~$55 million. The big problem is the ongoing large losses. The company plans to get quarterly operating expenses down to $40 million, but Tilray only generates gross margins in the 29% range.My biggest issue is that Tilray is plugged into a lot of different business with Canadian cannabis, U.S. hemp and international operations causing the large expense base. If the company had the balance sheet of Canopy Growth or Aphria, the spending levels wouldn’t be a problem.Tilray ended March with $174 million in cash and had to raise $60 million in debt during February before completing an equity offering. Back in March, the company sold 7.25 million shares and warrants for net proceeds of $90.4 million.Analysts have Tilray losing money for the next couple of years and the market isn’t going to find money-losing cannabis stocks very appealing in this environment. Investors should watch for the Canadian cannabis company to drastically reduce the quarterly EBITDA losses after losing another $21 million in Q1. Once Tilray gets to a position where additional funds aren’t needed, the stock can be removed from the 'avoid' list.To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclosure: No position.

Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.

A big challenge with investing in pot stocks is that bad returns by one company can send all the others into a tailspin. Aphria (NYSE: APHA) is a good example. Profits are rare in the cannabis industry.

Aphria cited 'cost effectiveness' and its focus on social responsibility to explain the move.